Gain the Decision Advantage
Breakthrough 2027 brings together life sciences leaders, industry regulators and experts, to explore the future of AI in life sciences.
ArisGlobal successfully delivered the industry’s largest drug safety system implementation, going live on-time with its next-generation LifeSphere® MultiVigilance offering. LifeSphere MultiVigilance 10 is the industry’s only end-to-end safety system offering production-ready automation.
ArisGlobal is proud to announce that ten life sciences companies have switched to its industry-leading LifeSphere® MultiVigilance drug safety system within the past 12 months. LifeSphere MultiVigilance is a next-generation, end-to-end safety system that has been developed in close partnership with industry leaders, including the FDA, Boehringer Ingelheim, Teva and AbbVie, among others.
ArisGlobal, the visionary technology provider of automated solutions for the life sciences industry, today announced the availability of LifeSphere® LitPro (LSLP), the life science industry’s first and only solution that effectively automates all steps in the medical literature monitoring (MLM) process required by most regulatory agencies.
ArisGlobal, the visionary provider of drug development technology for the life sciences industry, today announced the availability of LifeSphere® MultiVigilance 10 (LSMV10), the industry’s only end-to-end drug safety system with production-ready automation.
Santen Pharmaceutical Co., Ltd., the leader in ophtalmicdrug development, has selected ArisGlobal to create a single global safety database and improve the efficiency and quality of their global safety vigilance processes. Santen Pharmaceutical’s safety suite will include ArisGlobal’s LifeSphere® MultiVigilance (LSMV), LifeSphere® Reporting and Analytics and LifeSphere® Intake and Triage solutions to automate key safety vigilance activities, reduce costs, and increase compliance.
ArisGlobal today announced details of its annual Life Sciences Technology Summit (AGLSTS 2019), taking place October 1st – 3rd at the Miami Beach EDITION hotel in Miami Beach, Florida. The 3-day event will bring together senior executives, IT and business practitioners, and industry experts across drug safety, regulatory affairs, clinical development, and medical affairs to discuss how a unified platform and automation technology can transform the drug development process.
ArisGlobal, LLC, a leading provider of life sciences software that automates core drug development functions for over 250 life sciences companies, will present a session titled “How to Fully Leverage Automation in PV – A Real Case Study” at the upcoming World Drug Safety Congress Europe 2019, September 10-11, 2019 at the Hotel Hilton Amsterdam, Amsterdam, Netherlands.
Nordic Capital, a leading private equity investor with deep experience in healthcare and technology has entered into a definitive agreement to acquire ArisGlobal.
Miami, Florida – May 2, 2019 – ArisGlobal, LLC, a ...
ArisGlobal, LLC, a leading provider of life sciences software will present a session titled “Are You Ready for the New Era in PV?” at the upcoming World Drug Safety Congress Americas 2019
ArisGlobal is a pivotal partner in the life sciences industry, specializing in solutions that drive drug development, safety monitoring, and regulatory compliance. We collaborate with more than 220 global life sciences companies, CROs, and government health authorities, including leading biopharmaceutical firms and regulatory bodies such as FDA, Health Canada, and NMPA.
Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China.
Quick Links
© 2026 ArisGlobal – All Rights Reserved